Resistance to first‐generation somatostatin receptor ligands does not impair the results of gamma knife radiosurgery in acromegaly
- 4 July 2021
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 95 (6) , 849-855
Abstract
Objective: Gamma knife radiosurgery (GKRS) has proven to be an effective adjuvant treatment for patients with acromegaly. We performed the present study to investigate, which would be the outcome of GKRS, independently on the response to somatostatin receptor ligand (SRL).Design: Retrospective, observational study.Patients: Ninety‐six patients with active acromegaly were included.Measurements: The cumulative probability of normalisation of insulin‐like growth factor 1 (IGF‐1) levels after GKRS was assessed by the Kaplan–Meier method. The association of several clinical characteristics with GKRS outcomes was explored with the use of a Cox proportional‐hazard model with the relative hazard ratio and 95% confidence interval (CI).Results: Resistance to SRL occurred in 39 of the 96 patients (40.6%). After GKRS, patients resistant to SRL had a 5‐ and 10‐year probability of remission of 40.7% (95% CI: 23.7%–57.7%) and 75.9% (95% CI: 57.9%–93.9%), respectively. Patients responding to SRL had a 5‐ and 10‐year probability of remission of 46.8% (95% CI: 32.2%–61.4%) and 58.1% (95% CI: 41.5%–74.7%), respectively. The difference was not significant (p = .48 by the log‐rank test). Multivariate Cox analysis confirmed that the only independent variables associated with GKRS outcome were basal growth hormone (GH; p = .001) and IGF‐1 multiple of the upper limit of normal levels before GKRS (p = .013).Conclusion: We demonstrate for the first time that the responsiveness to SRL has no effect on the probability to obtain remission of acromegaly after GKRS. The remission of disease occurred more frequently in patients who had lower GH and IGF‐1 levels before GKRS.Keywords
This publication has 25 references indexed in Scilit:
- Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) DatabaseEndocrine-Related Cancer, 2017
- Mortality in acromegaly: a 20-year follow-up studyEndocrine-Related Cancer, 2016
- Acromegaly: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2014
- A consensus on the diagnosis and treatment of acromegaly complicationsPituitary, 2012
- Gamma knife radiosurgery for clinically persistent acromegalyJournal of Neuro-Oncology, 2012
- Gamma Knife Radiosurgery for AcromegalyInternational Journal of Endocrinology, 2012
- Factors Influencing Mortality in AcromegalyThe Journal of Clinical Endocrinology & Metabolism, 2004
- How effective are current therapies for acromegaly?Growth Hormone & IGF Research, 2003
- Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonistThe Lancet, 2001
- Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist PegvisomantNew England Journal of Medicine, 2000